Cytokinetics, Inc. : Cytokinetics to Present at Upcoming Healthcare Conferences

     Cytokinetics, Inc. : Cytokinetics to Present at Upcoming Healthcare

South San Francisco, CA, March 29, 2013 - Cytokinetics, Incorporated  (Nasdaq: 
CYTK) announced  today that  Robert  I. Blum,  President and  Chief  Executive 
Officer,  is  scheduled  to  present  a  corporate  update  at  the  following 
healthcare conferences:

Future Leaders in the Biotechnology Industry Conference
Date: Friday, April 5, 2013
Time: 9:00 AM Eastern Time
Location: Millennium Hotel, New York, NY

Needham 12^th Annual Healthcare Conference
Date: Monday, May 1, 2013
Time: 10:40 AM Eastern Time
Location: Westin New York Grand Central, New York, NY

Interested parties  may  access the  live  audio  and slide  webcast  of  this 
presentation by visiting  the Investor Relations  section of the  Cytokinetics 
website at The webcast  replay of the presentation  will 
be archived on the Presentations page within the Investor Relations section of
Cytokinetics' website for two weeks following the completion of the event.

About Cytokinetics

Cytokinetics is  a clinical-stage  biopharmaceutical  company focused  on  the 
discovery and development of novel  small molecule therapeutics that  modulate 
muscle function for the  potential treatment of  serious diseases and  medical 
conditions.  Cytokinetics'  lead  drug  candidate  from  its  cardiac   muscle 
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment  of heart failure. Amgen  Inc. holds an  exclusive 
license worldwide  (excluding Japan)  to develop  and commercialize  omecamtiv 
mecarbil and related compounds, subject to Cytokinetics' specified development
and commercialization  participation  rights.  Cytokinetics  is  independently 
developing tirasemtiv and CK-2127107, both fast skeletal muscle activators, as
potential treatments  for  diseases  and medical  conditions  associated  with 
aging, muscle wasting  or neuromuscular dysfunction.  Tirasemtiv is  currently 
the subject of a Phase II clinical trials program and has been granted  orphan 
drug  designation  and  fast   track  status  by  the   U.S.  Food  and   Drug 
Administration and  orphan  medicinal  product  designation  by  the  European 
Medicines Agency for the potential treatment of amyotrophic lateral sclerosis,
a debilitating disease  of neuromuscular  impairment in  which treatment  with 
tirasemtiv produced potentially clinically relevant pharmacodynamic effects in
Phase II trials. All of these  drug candidates have arisen from  Cytokinetics' 
muscle biology  focused  research  activities and  are  directed  towards  the 
cytoskeleton. The  cytoskeleton is  a complex  biological infrastructure  that 
plays a fundamental role within every human cell. Additional information about
Cytokinetics can be obtained at

This press release  contains forward-looking  statements for  purposes of  the 
Private Securities Litigation  Reform Act  of 1995  (the "Act").  Cytokinetics 
disclaims any intent or obligation to update these forward-looking statements,
and claims  the  protection  of  the Act's  safe  harbor  for  forward-looking 
statements. Examples  of such  statements  include, but  are not  limited  to, 
statements relating to planned presentations, and the properties and potential
benefits of Cytokinetics' drug candidates and potential drug candidates.  Such 
statements are based on management's current expectations, but actual  results 
may differ materially due to  various risks and uncertainties, including,  but 
not limited to, potential difficulties or delays in the development,  testing, 
regulatory approval  and  production  of  Cytokinetics'  drug  candidates  and 
potential drug candidates that could  slow or prevent clinical development  or 
product approval, including risks  that current and  past results of  clinical 
trials or preclinical studies may not be indicative of future clinical  trials 
results and that Cytokinetics' drug  candidates and potential drug  candidates 
may have unexpected adverse side  effects or inadequate therapeutic  efficacy. 
For  further  information   regarding  these  and   other  risks  related   to 
Cytokinetics' business, investors  should consult  Cytokinetics' filings  with 
the Securities and Exchange Commission.

Cytokinetics, Incorporated:                       
Joanna L. Goldstein   
Manager, Corporate Communications and Marketing
(650) 624-3000


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Cytokinetics, Inc. via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.